Clyra - About the company
Clyra is an unfunded company based in United States, founded in 2026. It operates as a Developer of blood based tumor microenvironment profiling technology for oncology. Clyra has not raised any funding yet. The company has 471 active competitors, including 130 funded and 99 that have exited. Its top competitors include companies like Guardant Health, Natera and BillionToOne.
Company Details
Developer of blood based tumor microenvironment profiling technology for oncology. The platform analyzes routine blood samples to provide comprehensive data regarding cellular composition and activity within the tumor microenvironment. This approach facilitates longitudinal tracking of shifts in the tumor state during treatment. It supports oncology programs by assisting with patient selection, identification of response and resistance biomarkers, and the development of diagnostic strategies. The methodology allows for repeated measurements throughout clinical trials to inform translational research and decision making processes.
Key Metrics
Sign up to download Clyra's company profile
Clyra's funding and investors
Clyra has not raised any funding rounds yet.
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Clyra's Competitors and alternates
Top competitors of Clyra include Guardant Health, Natera and BillionToOne. Here is the list of Top 10 competitors of Clyra, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Guardant Health 2012, Redwood City (United States), Public | Developer of digital sequencing technology for cancer detection | $557M | 80/100 | |
2nd | Natera 2004, Redwood City (United States), Public | Developer of cell-free DNA testing for oncology, women’s health, and organ health | $152M | 79/100 | |
3rd | BillionToOne 2015, San Francisco (United States), Public | Provider of cell-free cancer liquid biopsy test | $389M | 71/100 | |
4th | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 67/100 | |
5th | Foundation Medicine 2010, Cambridge (United States), Acquired | Provider of genomics-based diagnostics test for cancer | $96.5M | 66/100 | |
6th | Myriad Genetics 1991, United States, Public | Developer of molecular diagnostics and personalized medicine for cancer | - | 66/100 | |
7th | NeoGenomics 2002, Fort Myers (United States), Public | Provider of cancer genetic diagnostic services | - | 65/100 | |
8th | Online platform for genetic and diagnostic health testing that helps identify health risks | $67.6M | 65/100 | ||
9th | Saga Diagnostics 2016, Morrisville (United States), Acquired | Provider of tests for detection and analysis of circulating tumor DNA | $17.9M | 65/100 | |
10th | Veracyte 2008, San Francisco (United States), Public | Developer of genomics-based diagnostics for cancer | $67.9M | 63/100 | |
601st |  Clyra 2026, United States, Unfunded | Developer of blood based tumor microenvironment profiling technology for oncology | - | - | - |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Clyra's competitors? Click here to see the top ones
Clyra's Investments and acquisitions
Clyra has made no investments or acquisitions yet.
Reports related to Clyra
Here is the latest report on Clyra's sector:
Are you a Founder ?
FAQs about Clyra
Explore our recently published companies
- Blackwood Advertising - Troy based, 2026 founded, Unfunded company
- Ask The Recruiter - San Francisco based, 2026 founded, Unfunded company
- Bit Byte - Salem based, 2026 founded, Unfunded company
- GeminAI Dx - Cambridge based, 2026 founded, Unfunded company
- BRANDM_BR - Brazil based, 2026 founded, Unfunded company
- Energzy-AI - 2026 founded, Unfunded company
